Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 4/20 | 0.40 |
| ▸ | MGLL | Q99685 | 4/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12019911 | 0.95 | TUBB4A (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29538691 | 0.92 | TUBB4A (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1971917 | 0.80 | DGAT1 (0.51) | DGAT1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL21904738 | 0.80 | DGAT1 (0.51) | DGAT1KDM4EALDH1A1MAPTHTT | |
| SCHEMBL23883165 | 0.79 | TUBB4A (0.40) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29803806 | 0.79 | TUBB4A (0.41) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29358044 | 0.76 | FAAH (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL153587 | 0.76 | FAAH (0.34) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL12414507 | 0.75 | MGLL (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29442798 | 0.74 | FAAH (0.39) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728304-B1 | SOLID PHASE SYNTHESIS OF ACYLATED PEPTIDES | BACHEM HOLDING AG (CH) | 2025-02-12 | — | — | EP | claimed |
| EP-4126862-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. (US) | 2023-02-08 | — | — | EP | claimed |
| EP-4320138-B1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| EP-4605403-B1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-20250282813-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM HOLDING AG (CH) | 2025-09-11 | — | — | US | disclosed |
| EP-4613745-A2 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | Gilead Sciences, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4605403-A1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | Bachem Holding AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| US-12365666-B2 | Process for preparing a Cot inhibitor compound | GILEAD SCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4126862-B1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3728304-B1 | SOLID PHASE SYNTHESIS OF ACYLATED PEPTIDES | BACHEM HOLDING AG (CH) | 2025-02-12 | — | — | EP | disclosed |
| US-20240199579-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2024083746-A1 | METHOD AND COMPOSITION FOR OLIGONUCLEOTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2024-04-25 | — | — | WO | disclosed |
| EP-4320138-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | Bachem Holding AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| US-11845737-B2 | Process for preparing a Cot inhibitor compound | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| WO-2023117904-A1 | METHOD FOR PEPTIDE SYNTHESIS | BACHEM HOLDING AG (CH) | 2023-06-29 | — | — | WO | disclosed |
| US-20230057232-A1 | ISOTOPICALLY LABELED BILE ACID DERIVATIVES | INTERCEPT PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4126862-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220380340-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. | 2022-12-01 | — | — | US | disclosed |
| US-11472831-B2 | Isotopically labeled bile acid derivatives | INTERCEPT PHARMACEUTICALS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| WO-2022214692-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | BACHEM HOLDING AG (CH) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845737-B2 | Process for preparing a Cot inhibitor compound | TPO, TFPI, TFPI2 | TUBB4A 1068/4885TUBB 765/4885TUBA3C 928/4885 |
| US-20220380340-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | TPO, TFPI, TFPI2 | TUBB4A 1068/4885TUBB 765/4885TUBA3C 928/4885 |
| US-20240199579-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | TPO, TFPI, TFPI2 | TUBB4A 1068/4885TUBB 765/4885TUBA3C 928/4885 |
| US-12365666-B2 | Process for preparing a Cot inhibitor compound | TPO, TFPI, TFPI2 | TUBB4A 1068/4885TUBB 765/4885TUBA3C 928/4885 |
| US-20230057232-A1 | ISOTOPICALLY LABELED BILE ACID DERIVATIVES | SLC10A2, SLC10A1, NR1H4 | TUBB4A 127/4885TUBB 83/4885TUBA3C 191/4885 |
| US-11472831-B2 | Isotopically labeled bile acid derivatives | SLC10A2, SLC10A1, NR1H4 | TUBB4A 153/4885TUBB 117/4885TUBA3C 187/4885 |
| US-20250282813-A1 | PSEUDO SOLID PHASE PROTECTING GROUP AND METHODS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND OLIGONUCLEOTIDE CONJUGATES | POLR2H, POLR2E, SUB1 | TUBB4A 3295/4885TUBB 2589/4885TUBA3C 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.